接受伏立康唑预防治疗的造血干细胞移植受者中的侵袭性毛霉菌病
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
作者信息
Siwek Greg T, Dodgson Kirsty J, de Magalhaes-Silverman Margarida, Bartelt Luther A, Kilborn Sara B, Hoth Peter L, Diekema Daniel J, Pfaller Michael A
机构信息
Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA.
出版信息
Clin Infect Dis. 2004 Aug 15;39(4):584-7. doi: 10.1086/422723. Epub 2004 Jul 30.
We report 4 cases of invasive zygomycosis in hematopoietic stem cell transplant recipients, all occurring after May 2003, when voriconazole began to be used as antifungal prophylaxis. No cases of zygomycosis had been detected in this population in the 3 years prior to May 2003. All 4 patients were receiving immunosuppressive therapy for presumed graft-versus-host disease. Profoundly immunosuppressed patients receiving voriconazole prophylaxis remain at risk for less-common pathogens that are intrinsically resistant to this agent.
我们报告了4例造血干细胞移植受者侵袭性接合菌病病例，均发生在2003年5月之后，当时伏立康唑开始用作抗真菌预防药物。在2003年5月之前的3年里，该人群中未检测到接合菌病病例。所有4例患者均因疑似移植物抗宿主病而接受免疫抑制治疗。接受伏立康唑预防治疗的深度免疫抑制患者，仍面临感染对该药物具有固有耐药性的罕见病原体的风险。
Zotero 插件